as declared in news
Greens call for HIV prevention drug import
Greens call for HIV prevention drug import
Australian Associated PressThe Australian Greens want the government to pay for people to import a HIV prevention drug that has failed to receive taxpayer subsidisation.Truvada - a once-daily pill that costs around $750 a month and is aimed at preventing HIV transmission - was rejected for listing on the Pharmaceutical Benefits Scheme.The Department Of Health said the price requested by the drugmaker, Gilead Sciences, was too high and it was not feasible to limit the drug to a smaller, high-risk subset of the whole "at risk" population.
as well scidev
HIV prevention drugs could halve new cases
HIV prevention drugs could halve new cases
[DURBAN] People at high risk of contracting a HIV infection could be protected by taking anti-retroviral medicines (ARV) regularly, a conference in Durban, South Africa, has heard.The studies were presented at the 21st International AIDS Conference in South Africa last month (18-22 July).The so-called ASPIRE trial, undertaken by the United States' Microbicide Trials Network, delivered a monthly vaginal ring coated in dapivirine, an ARV, to 2,600 HIV-negative women from Malawi, South Africa, Uganda and Zimbabwe.Earlier this year, results showed the monthly ring reduced the risk of infection by 25 per cent.After further analyses, that figure has now risen to more than 50 per cent.Jared Baeten, a professor of global health at the US-based University of Washington in Seattle, and ASPIRE chair, says the ring could offer significant protection."It's reduced the risk by half in women over 21.
moreover from theguardian
Health department won't subsidise HIV prevention drug
Health department won't subsidise HIV prevention drug
An HIV prevention drug will not be taxpayer-subsidised after it failed to receive recommendation to the Pharmaceutical Benefits Scheme.An application to list Truvada – a once-daily pill that costs about $750 a month and is aimed at preventing HIV transmission – was rejected on Friday by the Pharmaceutical Benefits Advisory Committee.The Department Of Health said the price requested by the maker, Gilead Sciences, was far too high and it was not feasible to limit the drug to a smaller, high-risk subset of the whole "at risk" population.
No comments:
Post a Comment